|
2007P-0216: Determine that an Additional Dosage of Deferoxamine Mesylate for Injection, USP is Suitable for an Abbreviated New Drug Application (ANDA)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed Date
|
| Submitter Code
|
| Submitter
|
| FR Date
|
| FR Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 05/30/2007
|
| 05/30/2007
|
| Private
Industry
|
| Ben Venue
Laboratories, Inc.
|
|
|
|
|
|
|
| html
|
|
|
|
|
| Signature:
|
| Molly L. Rapp
|
|
|
|
|
| ACK1
|
| 05/30/2007
|
| 05/30/2007
|
| Federal
Government
|
| FDA/DDM to Ben Venue
Laboratories, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
| Signature:
|
| Gloria Ortega
|
|
|
|
|
|
|
|
|
Top | Page last updated:
June 1, 2007
|
